Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 717530, 12 pages
http://dx.doi.org/10.1155/2015/717530
Review Article

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme

1Department of Neurology, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China
2Department of Neurosurgery, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China

Received 25 September 2014; Accepted 8 January 2015

Academic Editor: Yung-Fu Chang

Copyright © 2015 Liu Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glioblastoma multiforme (GBM) is the most malignant glioma and patients diagnosed with this disease had poor outcomes even treated with the combination of conventional treatment (surgery, chemotherapy, and radiation). Dendritic cells (DCs) are the most powerful antigen presenting cells and DC-based vaccination has the potential to target and eliminate GBM cells and enhance the responses of these cells to the existing therapies with minimal damage to the healthy tissues around them. It can enhance recognition of GBM cells by the patients’ immune system and activate vast, potent, and long-lasting immune reactions to eliminate them. Therefore, this therapy can prolong the survival of GBM patients and has wide and bright future in the treatment of GBM. Also, the efficacy of this therapy can be strengthened in several ways at some degree: the manipulation of immune regulatory components or costimulatory molecules on DCs; the appropriate choices of antigens for loading to enhance the effectiveness of the therapy; regulation of positive regulators or negative regulators in GBM microenvironment.